

| |
|--------------------------------------|
| PATENT ASSIGNMENT COVER SHEET |
|--------------------------------------|

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4751849

| | |
|---|-------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| PERSEUS PROTEOMICS INC. | 11/15/2017 |
| RECEIVING PARTY DATA | |
| Name: | SAVID THERAPEUTICS INC. |
| Street Address: | 2-1-11 KACHIDOKI, CHUO-KU |
| City: | TOKYO |
| State/Country: | JAPAN |
| Postal Code: | 104-0054 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 13202102 |
| CORRESPONDENCE DATA | |
| Fax Number: | (703)716-1180 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 703-716-1191 |
| Email: | gbpatent@gbpatent.com |
| Correspondent Name: | GREENBLUM & BERNSTEIN, P.L.C. |
| Address Line 1: | 1950 ROLAND CLARKE PLACE |
| Address Line 4: | RESTON, VIRGINIA 20191 |
| ATTORNEY DOCKET NUMBER: | P40631 |
| NAME OF SUBMITTER: | WALTER A. SCHLAPKOHL |
| SIGNATURE: | /Walter Schlapkohl/ |
| DATE SIGNED: | 12/27/2017 |
| Total Attachments: 3 | |
| source=P40631_Assignment#page1.tif | |
| source=P40631_Assignment#page2.tif | |
| source=P40631_Assignment#page3.tif | |

ASSIGNMENT

WHEREAS, **THE UNIVERSITY OF TOKYO**, a corporation organized and existing under the laws of JAPAN, whose post office address is 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo, 113-8654 JAPAN, and **PERSEUS PROTEOMICS INC.**, a corporation organized and existing under the laws of JAPAN, whose post office address is Park Bldg., 7-6, Komaba 4-chome, Meguro-ku, Tokyo, 153-0041 JAPAN, hereinafter known as the ASSIGNOR, are the owners of U.S. Patent No. 8,546,537 entitled

STREPTAVIDIN HAVING LOW IMMUNOGENICITY AND USE THEREOF

issued on October 1, 2013, from U.S. Patent Application No. 13/202,102, and any and all divisions and continuations thereof, and any and all Letters Patent which may be granted therefor including any and all renewals, reissues, reexaminations, extensions, adjustments, and prolongations thereof (hereinafter collectively known as the PATENT) by means of an Assignment recorded October 31, 2011, at Reel 027148, Frame 0507 of the U.S. Patent and Trademark Office assignment records.

AND WHEREAS, **SAVID THERAPEUTICS INC.**, a corporation organized and existing under the laws of JAPAN, whose mailing address is 2-1-11 Kachidoki, Chuo-ku, Tokyo 104-0054 JAPAN, hereinafter known as the ASSIGNEE, is desirous of acquiring ASSIGNOR'S entire right, title and interest for the United States in and to the PATENT, such that ASSIGNEE and **THE UNIVERSITY OF TOKYO** shall be co-owners, each owning an equal undivided interest of the entire right, title and interest for the United States in and to the PATENT.

NOW, THIS WITNESSETH that for good and valuable consideration, the receipt and sufficiency whereof is hereby acknowledged, said ASSIGNOR hereby assigns, sells and transfers to said ASSIGNEE, its assigns and legal representatives, ASSIGNOR'S entire right, title and interest in and to the PATENT for the United States and all rights to sue for past and future infringement thereunder, said ASSIGNEE and its assigns and legal representatives to have, hold, exercise and enjoy the PATENT, with all the rights, powers, privileges, and advantages in any ways arising from or pertaining thereto, for and during the term or terms of any and all such Letters Patent when granted, including any and all renewals, reissues, reexaminations, and prolongations thereof, for the use and benefit of said ASSIGNEE and its assigns and legal representatives in as ample and beneficial a manner to all intents and purposes as the said ASSIGNOR might or could have held and enjoyed the same, if this assignment had not been made, such that ASSIGNEE and **THE UNIVERSITY OF TOKYO** are co-owners, each owning an equal undivided interest of the entire right, title and interest for the United States in and to the PATENT.

AND said ASSIGNOR hereby agrees to execute all papers necessary to file applications in the United States for ASSIGNEE's rights in said PATENT and to assign the same to said ASSIGNEE, or any assignee acquiring title to said PATENT, and to execute any other papers that may be needed in connection with filing said application and securing Letters Patent thereon.

AND said ASSIGNOR authorizes and requests the Commissioner of Patents to issue Letters Patent on said application, and on any and all divisions and continuations thereof, to said ASSIGNEE, its assigns and legal representatives, in accordance herewith.

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR, on the respective date(s) indicated below.

First Witness:

阿部 達志 (TADASHI)
(Name) TADASHI MATSUDRA

Nov. 15, 2017
(Date)



PERSEUS PROTEOMICS INC.
Yukio SUDO
President

Nov. 15 / 2017
Date


Second Witness:

Hilm Zhray
(Name)

Nov. 15, 2017
(Date)

IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNEE, on the respective date(s) indicated below.

First Witness:



(Name) Akira SUGIYAMA

Dec. 18, 2017
~~2017~~

(Date)



SAVID THERAPEUTICS INC.


Masanobu TSUKAGOSHI

Chief Executive Officer

Dec. 18, 2017

Date

Second Witness:



(Name) Tatsuhiko KODAMA

Dec. 18, 2017

(Date)